Kornimate/medical-research-clean huggingface dataset:
different doses of nebulized magnesium sulphate in status asthmaticus

Conditions: Status Asthmaticus

Summary: in this study investigators will use magnesium sulphate in the nebulized form in children between 2 and 12 years of age as an acute reliever for acute severe asthma. aim of this study is to determine that whether adding low (250mg), intermediate (500mg), and high doses (750mg) of magnesium sulphate in the 1st hour of treatment has any difference in the improvement of clinical condition of the patient and length of hospital stay. there will be total 108 patients having 2 groups. 1st group will receive only ventolin while 2nd group will be given ventolin and magnesium sulphate.

this randomized clinical trial will include 126 patients after taking informed consent who will meet the eligibility criteria. patients will be randomly distributed in 2 groups on alternate basis as computerized generated number. improvement will be assessed in terms of clinical condition i.e., heart rate, respiratory rate, blood pressure, pattern of breathing oxygen saturation and pediatric respiratory assessment measure (pram) score at start of treatment and then afterwards at 20 min interval up to 1 hour and then at 2nd hour and then after every 6 hours for 24 hours.

Eligibility criteria:
inclusion criteria: 1. children between 2 to 12 years of age. 2. children with the diagnosis of asthma having a pram score of more than 4. 3. children with reactive airways exclusion criteria: 1. critically ill children who require intubation or mechanical ventilation. 2. having hypersensitivity or allergy to mgso4. 3. with history of chronic lung impairment. 4. whose parents are not giving informed consent for participation in research.

Keywords: asthma nebulized magnesium sulphate
radiofrequency-assisted liver resection in intractable liver cancer

Conditions: Liver Cancer

Summary: in this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.

the primary clinical treatment of liver cancer is surgical resection, although many integrated applications develop rapidly, surgery is still the best way to remove the tumour lesion. traditional ways that have curative removed tumours in three methods, which are liver resection, liver transplantation and radiofrequency ablation (rfa). as for primary liver cancer, surgery, and rfa are both effective and safety, but for the complexity of end-stage liver cancer, surgical resection may not remove the tumours alone. surgical resection with radiofrequency ablation therapy for intractable liver cancer is a kind of active plan. the therapy can eliminate the tumour, maximize the protection of patient liver tissue, reduce operation damage, reduce the incidence of complications, and improve patients quality of life after surgery.

Eligibility criteria:
inclusion criteria: * ultrasound-guided fine-needle aspiration pathology or postoperative pathology was confirmed to be liver cancer, no pathological results according to china 's 2017 version of the hepatocarcinoma (hcc) diagnosis and treatment specifications, in line with the standard clinical diagnosis of liver cancer * according to barcelona clinic liver cancer (bclc) staging criteria, it is stage c (stage c: single tumour\> 5 cm or more than three tumours, and at least one tumour\> 3 cm, liver function child-pugh a or b, with lymph node metastasis or distant metastasis or portal vein or venous liver trunk is invaded, penance status (pst) score 1-2 points) exclusion criteria: * hcc patients with other malignant tumours * metastatic liver tumour * patients with liver abscess * patients with organ dysfunction

Keywords: rfa liver cancer surgical resection
effectiveness of a multifactorial intervention on frailty

Conditions: Frail Elderly; Cognitive Impairment; Dependence

Summary: objective: to evaluate the effectiveness of a multifactorial intervention program based on physical activity and diet, memory workshops and review of medication, to modify frailty parameters, muscle strength and physical and cognitive performance in people 65 years or older with a positive screening for frailty. secondly, to assess changes in falls, hospitalizations, nutritional risk, disability and institutionalization or home-care. methods: randomized clinical trial with a control group, of one year and a half of follow-up, conducted in eight primary care teams in barcelona. individuals to be included are 65 years or older with positive frailty screening, timed get-up-and-go between 10 to 30 seconds, and cognitive lobo test greater than or equal to 18. 165 patients will be selected in each group (difference to be detected on physical performance (short physical performance battery (sppb)): 0.5 units; common standard deviation : 1.42, 20% lost to follow-up). intervention: consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy plus intake of hyperproteic shakes, memory workshop and review of the medication. evaluations will be blinded and conducted at 0, 3 and 18 months. analysis of variance for repeated measures to adjust for differences attributable to intervention effect and for potential confounders such as comorbidity, sensory limitations, social risk, other medical or social interventions, among others.


Eligibility criteria:
inclusion criteria: * positive barber screen * timed get-up-and-go 10 to 20 seconds * cognitive lobo test greater than or equal to 18 exclusion criteria: * home care * institutionalization * conditions not allowing physical exercise

Keywords: frail elderly
study of arlocabtagene autoleucel (bms-986393) a gprc5d-directed car t cell therapy in adult participants with relapsed or refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to evaluate the effectiveness and safety of arlocabtagene autoleucel (bms-986393) in participants with relapsed or refractory multiple myeloma.


Eligibility criteria:
inclusion criteria * documented diagnosis of multiple myeloma (mm) as per international myeloma working group (imwg) criteria. * received at least 3 classes of mm treatment \[including immunomodulatory drug (imid), proteasome inhibitor (pi), anti cd38 mab, and at least 3 prior lines of therapy (lot). * documented disease progression during or after their last anti-myeloma regimen as per imwg 2016 criteria. * participants must have measurable disease during screening. * eastern cooperative oncology group (ecog) performance status of 0 or 1. exclusion criteria * active or history of central nervous system involvement with mm. * active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. * received any prior therapy directed at g protein-coupled receptor class c, group 5, member d (gprc5d) or has received other prior treatment for mm without the required washout prior to leukapheresis. * other protocol-defined inclusion/exclusion criteria apply.

Keywords: relapsed or refractory multiple myeloma multiple myeloma bms-986393 car t cell therapy rrmm arlocabtagene autoleucel
tools to identify people at risk or already infected with hiv and hcv

Conditions: HIV/AIDS; STD; HCV

Summary: wedge-shaped clusterded randomizad trial to evaluate two tools to identify people at risk or already infected with hiv and hcv

objectives: to reduce hidden and incident hiv and hcv infection, through the implementation of a risk and indicator conditions self-questionnaire sq-r\&ic for hiv and hcv infection, in addition to rapid hiv and hcv serological tests (rt), in the health centers (hc). methodology: stepped-wedge cluster randomized trial in 8 cs of the community of madrid, to to know if the implementation of the 2 tools described above, improve risk identification and subsequent screening for hiv and hcv infection. in the standard of care branch (soc), the health personnel will ask people a series of questions to identify the hiv risk exposition, and also they will be provided pop-up computer alerts of hiv indicator conditions in the electronic medical record, moreover hiv and hcv serological tests will be carried out in the reference laboratory, while in the intervention branch in addition to the soc, a sq-r\&ic of hiv and hcv will be made available to the hc population, through a quick response (qr) code, as well as hiv and hcv rt. the variables that will be compared are the percentage of hiv and hcv tests performed, of people referred to receive prep, and of new hiv and hcv diagnoses or not linked to care that are made during the periods assigned to the edc branch vs. those in the intervention branch.

Eligibility criteria:
inclusion criteria: - 14-65 years in the health area or who are captured for inclusion by health personnel. they give their consent to participate. exclusion criteria: * having already been included in the study, not signing the consent.
impact of intrathecal morphine on sleep apnea syndrome

Conditions: Sleep Apnea Syndromes

Summary: intrathecal morphine is commonly used as an analgesic adjunct for hip arthroplasty performed under spinal anaesthesia. sleep apnea syndrome is a condition that affects up to 10% of the patients. effect of intrathecal hydrophilic opioids on the frequency and duration of apneic episodes is unknown. the objective of this randomised controlled trial is to investigate the effect of intrathecal morphine and surgery on apneic episodes.


Eligibility criteria:
inclusion criteria: * physical status i - iii * patients scheduled to undergo hip arthroplasty exclusion criteria: * planned surgical duration more than 3 hours * contraindication to spinal anaesthesia * severe respiratory disease * patient known and treated for sleep apnea syndrome
effectiveness study of gsk biologicals' rotarix tm vaccine in hospitalized children

Conditions: Infections, Rotavirus; Rotavirus Vaccines

Summary: the purpose of this study is to assess vaccine effectiveness of rotarix in preventing rotavirus severe gastroenteritis among hospitalized infants, in belgium.


Eligibility criteria:
inclusion criteria: for confirmed cases: * a male or female child born after 01 october 2006 and at least 14 weeks of age at the time of hospital admission. * child admitted at the study hospital for sge during the study period. * onset of sge ≤ 14 days prior to admission. * written informed consent obtained and signed from the parent or guardian of the child. * stool samples collected during the first 48 hours of hospitalisation and then tested positive for rv by pcr. for controls: * a male or female child born after 01 october 2006 and at least 14 weeks of age at the time of the hospital admission or visit to the hospital outpatient clinic. * hospitalised or visiting the hospital outpatient clinic for non-ge causes at the same hospital during the same time-period, as the probable case. * born within ±2 weeks from the date of birth of the case. if the list of children born within ±2 weeks is exhausted, then the range will be extended to ±4 weeks. in case a suitable control is not found even then, the range will be extended to ±6 weeks. * written informed consent obtained and signed from the parent or guardian of the child. exclusion criteria: for cases: * child has previously participated as a case or a control in this study, either in the same hospital or in another study hospital. * onset of sge \>48 hours after admission to the hospital (nosocomial infections). * child with a condition where rotavirus vaccination would be contraindicated. for controls: * child has participated in the past as a case or control in this study, either in the same hospital or in another study hospital. * child who has symptoms of ge/ sge during current hospital stay/ visit to the hospital outpatient clinic or on the day of interview of his/her parent or guardian. * child with a condition where rotavirus vaccination would be contraindicated.

Keywords: hospitalized rotavirus children effectiveness gastroenteritis
pectointercostal fascial plane block chronic pain sternotomy

Conditions: Chronic Pain

Summary: this study aims to compare the effect of pectointercostal fascial plane block (pifb) on postoperative chronic pain in patients undergoing open heart surgery with the standard multimodal analgesia technique.

chronic postsurgical pain (cpsp), defined as persistent pain at the surgical site or referred areas lasting at least three months post-surgery, poses a considerable challenge, notably after median sternotomy in cardiac procedures. incidence rates, ranging from 28% to 56% within two years post-operation, exhibit variability, partly due to diverse presentations and potential underreporting by patients. the psychological impact of cardiac surgery often leads patients to normalize enduring pain, delaying the identification of chronic post-sternotomy pain. the multifaceted etiology of cpsp after sternotomy remains incompletely understood. factors such as neural sensitization during the acute phase, neuropathy from nerve entrapment or injury during surgery, musculoskeletal trauma from incisions, sternal complications, and infections contribute to this complex pain landscape. inadequate management of acute perioperative pain can trigger central sensitization, a process-altering spinal pain pathway, and predispose individuals to hyperalgesia and chronic pain. thus, effective acute pain control not only alleviates immediate postoperative discomfort but also potentially averts the onset of chronic pain. traditionally, opioids like fentanyl and morphine have been primary choices for post-cardiac surgery pain relief. however, their use is associated with dose-related side effects such as nausea, respiratory issues, chronic opioid dependence, and increased chronic pain risk. implementing a multimodal approach, including nsaids, proves challenging due to bleeding and renal complications post-cardiac surgery. in contrast, regional analgesia offers an opioid-sparing alternative. parasternal regional blocks like the pectointercostal fascial plane block (pifb) present a low-risk option and have demonstrated efficacy in alleviating acute post-sternotomy pain. addressing this, a prospective, double-blinded randomized controlled trial aimed to evaluate whether a pif block could provide effective perioperative analgesia and potentially mitigate the incidence of cpsp in patients undergoing sternotomy for cardiac surgery.

Eligibility criteria:
inclusion criteria: * asa 3 risk score patients scheduled for elective open heart surgery exclusion criteria: * emergent surgery * previous thoracotomy * lvef \<30 * patients with psychiatric disorders * presence of hematological disease * patients with alcohol-drug addiction * patients who use daily opioids for any reason * chronic analgesic use * allergy to local anesthetics * bmi \>40
nutritional deficiencies preventive treatment prior to laparoscopic sleeve gastrectomy

Conditions: Disorder of Bone Density and Structure, Unspecified; Vitamin D Deficiency

Summary: this study will examine the effect of providing a structured program of daily nutritional supplements for a 8 weeks of intervention prior to sleeve gastrectomy bariatric surgery on bone mass density status and formation of critical nutritional deficiencies years after the surgery.

the present study hypothesis holds that providing an adequate nutritional supplements program prior to the surgery, combined with postoperative monitoring, will significantly lower the incidence of nutritional deficiencies in patients undergoing sleeve gastrectomy surgery, and will reduce complications arising from these pre-operative deficiencies. the investigators plan to examine the effect of vitamins supplementation prior to surgery on the status of postoperative deficiencies one year after the surgery. evaluation of outcomes will be made based on the results of blood tests specified, and related tests of bone density.

Eligibility criteria:
inclusion criteria: * candidates for bariatric surgery * bmi over 35 kg / m 2 accompanying morbidity or bmi over 40 kg / m 2, * pre-operative evaluation standards with matching to carry sleeve gastrectomy surgery * vitamin d deficiency prior to surgery exclusion criteria: * patients who underwent bariatric surgery in the past * psychiatric or mentally contraindication for the procedure * lack of consent to follow-up * endocrine problem that affects the weight that is unbalanced. * chronic kidney disease (ckd), nephrolithiasis * hypercalcaemia * hypercalciuria and renal stones nephrolithiasis * pregnancy, breastfeeding * using medications or disease condition known as affecting the status of calcium or bone metabolism 3 month prior to intervention * taking any nutritional supplements 2 weeks before the study.
desipramine hydrochloride and filgrastim for stem cell mobilization in patients with multiple myeloma undergoing stem cell transplant

Conditions: DS (Durie/Salmon) Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma; Refractory Plasma Cell Myeloma

Summary: this pilot clinical trial studied how well desipramine hydrochloride and filgrastim worked for stem cell mobilization in participants with multiple myeloma (mm) undergoing stem cell transplant. giving colony-stimulating factors, such as filgrastim, and other drugs, such as desipramine hydrochloride, helps stem cells move from the participant's bone marrow to the blood so they can be collected and stored.

primary objectives: i. to study efficacy, safety, harvest kinetics and engraftment kinetics of participants undergoing autologous stem cell mobilization, mobilized with a combination of granulocyte colony-stimulating factor (gcsf) (filgrastim) with desipramine (desipramine hydrochloride) (g+d). ii. to analyze polymorphisms of adrenergic receptor beta 2 (adrb2) and adrenergic receptor beta 3 (adrb3) genes that correlate with mobilization efficiency. outline: participants received desipramine hydrochloride orally (po) daily on days -3 to +4 and filgrastim po twice daily (bid) on days 1-4. stem cell collection began on day 6. after completion of study treatment, participants were followed up to 1 week after completion of stem cell collection.

Eligibility criteria:
inclusion criteria: * patients eligible for autologous stem cell transplant for multiple myeloma; planned use of filgrastim (gcsf) for stem cell mobilization * ability to give informed consent * glomerular filtration rate (gfr) \> 30 ml/minute * liver function tests \< 2.5 x upper limit of normal (uln) * eastern cooperative oncology group (ecog) performance status (ps) 2 or less * based on prior therapy patients will be classified into two categories: * initial mobilizers with no exposure to alkylators * remobilizers or with prior exposure to alkylators or with greater than 5 cycles of lenalidomide therapy prior to mobilization exclusion criteria: * use of a monoamine oxidase inhibitor (mao-i) during or within 2 weeks of desipramine therapy * concomitant therapy with any drugs shown to have major interactions with desipramine * concurrent use of drugs that are contraindicated with desipramine * myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death; baseline corrected qt (qtc) \> 460 msec * active alcohol abuse * bipolar disorder * untreated active major depression * history of seizures in the past 3 years * pregnancy and lactation; refusal to use adequate contraception * uncontrolled thyroid disease * gcsf or pegfilgrastim use within 14 days prior to enrollment * bortezomib, revlimid or thalidomide use within 7 days of enrollment * patients with sickle cell disease
real-life treatment patterns with cyclin-dependent kinase inhibitors in advanced breast cancer in portugal - reveal study

Conditions: Hormone-receptor-positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Summary: this was a non-interventional (observational), retrospective, cohort study of women with hormone receptor (hr)-positive and human epidermal growth factor receptor-type 2 (her2)-negative advanced breast cancer who started treatment with cyclin-dependent kinase inhibitors (cdki) 4/6 (ribociclib or palbociclib) in portugal. this was a study of medication use patterns, based on information from the hospital pharmacies of the participating centers. patients who started a cdki 4/6 (ribociclib or palbociclib) between 1 march 2019 and 31 december 2019 were included and followed through 24 months. a follow-up occurred 6 months after the start of cdki 4/6 (ribociclib or palbociclib) to quantify the occurrence of dose changes.


Eligibility criteria:
inclusion criteria: * female. * aged 18 years or older at the time of starting therapy with cdki 4/6. * breast cancer diagnosis. * at least one record of ribociclib or palbociclib donation during the identification period. * registration of the first supply of ribociclib or palbociclib between 1 march 2019 and 31 december 2019. exclusion criteria: * patients with missing information regarding their date of birth and the date or quantity of the drug dispensed in any assignment were excluded.
volume parameters vs flow parameters in assessment of reversibility in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: * assess the differences between flow and volume responses after bronchodilator reversibility testing in patients over different clinical chronic obstructive pulmonary disease stages (gold stage i to gold stage iv). * study the correlation between the bronchodilator response and the severity of the disease.

chronic obstructive pulmonary disease is a common preventable and treatable disease characterized by persistent airflow limitation that is usually progressive. the diagnosis requires an evidence of obstructive pattern by spirometry measured before and after bronchodilators. the degree of reversibility of airflow obstruction differs between patients, and does not predict the response to bronchodilator therapy. it can be seen in terms of forced vital capacity (fvc) or forced expiratory volume in the first second (fev1),or inspiratory capacity (ic) or residual volume (rv).

Eligibility criteria:
inclusion criteria: * patients clinical diagnosis of chronic obstructive pulmonary disease * must be able to do pulmonary function test * age more than 40 years * stable chronic obstructive pulmonary disease patients exclusion criteria: any patients with a diagnosis of: * bronchial asthma * bronchiectasis * respiratory failure * decompensated core pulmonale * chronic obstructive pulmonary disease combined with any other respiratory disease